Beyond
the Crowd
Creating a New Family of Antibodies: Multi-Modal Therapeutics for Drug Resistant Cancers
Kenjockety Biotechnology is developing a new family of bispecific antibodies (BsAbs) to address the significant unmet need of drug resistance in patients with cancer. Our proprietary BASETM Platform is creating an extensive pipeline of new therapeutics by pairing our foundational antibodies that target Efflux Pumps (EPs) with antibodies to known Tumor Associated Antigen (TAA) targets, to construct BsAbs that more effectively target tumor cells versus normal cells. Learn more about our BASE Platform →
Efflux Pumps are complex membrane-spanning proteins that expel cellular toxins, metabolites, and also anti-cancer agents. Efflux Pump overexpression on cancer cells leads to drug resistance and poor prognosis. Prior attempts to address Efflux Pump-related drug resistance focused on the use of small molecules. These efforts were unsuccessful largely due to lack of tumor specificity resulting in toxicity or other complications inherent in the small molecule approach.
